Key result
Modern dyslipidemia management targets LDL-C reduction through lifestyle modification and statins to cut cardiovascular risk.
Why the study?
Dyslipidemias are common in the general population and patients with cardiovascular disease, with evolving understanding of their pathophysiology and management.
Answers are grounded in this paper and cite their sources.
Supports LDL-centric dyslipidemia care; leaves open adjunctive strategies in resistant or diverse populations.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Yoto Trifonov Yotov (2015) conducted a review in Dyslipidemia. Lipid-lowering therapies was evaluated. Dyslipidemias are a major risk factor for cardiovascular diseases, and their modern management focuses on reducing LDL cholesterol as a primary target through lifestyle changes and statin therapy.
Synapse has enriched 10 related papers. Consider them for comparative context: